Lectin protein prepared from korean marine crab philyra pisum, process for preparing the same and the use thereof

ABSTRACT

The present invention relates to a Lectin protein prepared from Korean marine crab  Philyra pisum , process for preparing the same and the use thereof. This protein can be used as a diagnosing agent or a carrier protein that chemically binds to various anti-cancer drugs owing to its capability that specifically recognizes N-glycolylneuraminic acid, and, in addition, used as an anti-cancer drug in view of its anti-proliferation effect. cer drug in view of its anti-proliferation effect.

TECHNICAL FIELD

[0001] The present invention relates to a lectin protein isolated from Korean marine crab, Philyra pisum in the family Leucosiidae, a process for preparing the same and the use thereof. More specifically, the present invention relates to a lectin PPA (Philyra pisum agglutinin) that is a protein component isolated from the hemolymph of Korean marine crab Philyra pisum and specifically binds to N-glycolylneuraminic acid, a process for isolating and purifying the same, and the various uses of the PPA based on its biological activities.

BACKGROUND ART

[0002] In general, differentiation and growth as an intercellular recognition and interaction processes in a normal living body not affected by a disease are considered as an essential process in the vital phenomenon. Abnormality occurring in the differentiation and growth may causes incomplete development, malformation or cancer in cells. With the recent understanding of the vital phenomenon at the gene and protein levels, the roles of carbohydrates on the cell membrane surface have lately been given a great attention as a substance that enables the understanding of the vital phenomenon in the molecular level. As an example thereof, it is reported that the structural change of carbohydrate on the cell membrane surface is observed from the process of malignant degeneration of animal cells by viruses and the like, and that the abnormality of carbohydrates on the cell membrane commonly occurs in most of cancer cells. A dramatic change of the carbohydrate structure has also been reported in the development and differentiation processes.

[0003] Intercellular recognition occurs by way of carbohydrates on the cell membrane surface, and in order to mediate this process molecules specifically recognizing the carbohydrates should exist on the cell membrane surface. For example, a carbohydrate-binding protein such as lectin is necessary on the cell membrane surface.

[0004]Philyra pisum, which belongs to the family of Leucosiidae, is distributed throughout the mud areas of the west coast in Korea and characterized by a habit of walking forward unlike the other crabs, and slow and is feigning death when touched. Philyra pisum has not been used for food, and thus, biochemical researches thereon are very poor.

DISCLOSURE OF INVENTION

[0005] The present inventors have extensively been studied in order to characterize and test biological activity of the glycoprotein, lectin PPA the presence of which has not been known hitherto by isolating it from the hemolymph of Korean marine crab Philyra pisum by a method which will be described below, and as a result found that it has various beneficial biochemical characteristics such as a specific binding to N-glycolylneuraminic acid and thus can be used as diagnostics for various diseases including cancers, an anti-proliferation agent against cancer cells and a carrier protein for treating diseases, and completed the present invention.

[0006] It is therefore an object of the present invention to provide a lectin protein which was isolated from the hemolymph of Korean marine crab Philyra pisum and is a kind of proteins which specifically recognize N-glycolylneuraminic acid.

[0007] It is another object of the present invention to provide a process for preparing the lectin PPA.

[0008] It is further object of the present invention to provide diagnostics for a disease in which the structure of carbohydrates within the cells is modified to N-glycolylneuraminic acid that does not exist in a normal living body, which comprises the lectin PPA.

[0009] It is still another object of the present invention to provide a use of the lectin PPA as an anti-cancer drug with an anti-proliferation effect on cancer cells.

[0010] It is still further object of the present invention to provide a drug conjugate in which the lectin PPA as a carrier protein for local transport of a drug and, as an active agent (for example, an anti-cancer-drug), a drug which selectively binds to a specific cancer cell are chemically bonded.

BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Further objects and advantages of the invention can be more fully understood from the following detailed description taken in conjunction with the accompanying drawings in which:

[0012]FIG. 1 is a graph showing a UV (280 nm) spectroscopic chromatogram of the lectin PPA prepared by the present invention;

[0013]FIG. 2 is a photograph showing an electrophoretic analysis of the lectin PPA prepared by the present invention, in which lane 1 is a molecular weight marker (200, 116, 97, 66, 45, 31, 22.1, 14.4, 6.5 kDa); lane 2 is a stock solution of crab Philyra pisum; lane 3 is isolated lectin PPA of crab Philyra pisum; and lane 4 is isolated lectin PPA of crab Philyra pisum (with 2-mercaptoethanol); and

[0014]FIG. 3 is a graph showing the results of an ELISA (Enzyme-Linked Immunosorbent Assay) of the lectin PPA prepared by the present invention (O: fetuin; □: asialofetuin; and Δ: BSM).

BEST MODE FOR CARRYING OUT THE INVENTION

[0015] Hereinafter, the present invention will be described in further detail.

[0016] Lectins, which is a protein selectively binding to carbohydrates, has originally been discovered from plants, microorganisms, virus, invertebrates or vertebrates and widely used as a material for various disease-related researches. Lectin has various functions: it has been known to agglutinate erythrocytes to sediment them, and has been used in determining blood type. In addition, it has recently been known to have a function of specifically agglutinating cancer cells. Namely, lectin binds to a carbohydrate with a specific structure and thus enables selective communication between the cells with the lectin substance and the cells with a carbohydrate which binds to it.

[0017] Since the reports on the structural change of carbohydrate of proteins within the living body upon invasion of rheumatism, cancer or AIDS, there have been attempts to explain the results of these diseases in view of the structural changes of carbohydrate. Especially, it is considered that the remarkable change of sialyl epitopes in the sialoglycoconjugate of the surface of pathogenic or tumor cells results from the kind of sialic acid in the oligosaccharides or the carbohydrate binding pattern with the adjacent carbohydrates. Therefore, lectins specifically recognizing various sialic acids and their carbohydrate binding patterns can be used as a tool for identifying various sialyl epitopes in the biopsy of pathogens or malignant tumors.

[0018] Sialic acid refers to about 30 compounds including N-acetylneuraminic acid or its derivatives such as N-glycolylneuraminic acid, an acyl substituent at the C-5 amino group. Most of the other sialic acids have O-acetyl substituent(s) of one or more C-4, C-7, C-8 or C-9 hydroxyl groups. The thus substituted sialic acids may cause transformation or other changes in the cellular environment and has known to inhibit or weaken the sialic acid hydrolase of bacteria or viruses to change their immunity, thus affecting the enzyme activity in the catabolism of complex carbohydrates.

[0019] In particular, the antibody against the sialyl Le^(a) sugar shows an 80 to 90% positive response in the pancreatic cancer and the antibody against the sialyl Le^(x) sugar shows a positive response in gastrointestinal cancers. However, these responses are not caused by appearance of a new sugar due to canceration but by the change of the sugar synthetic pathway to change its ratio. Meanwhile, it was reported that sialic acids are upon invasion of diseases converted to N-glycolylneuranminic acid, for example, in the case of breast cancer, melanoma or colon cancer, and to an O-acetyl substituent in the case of ovarian cancer or melanoma (See Carr A et al., Hybridoma 19, pp. 241-247, (2000); and Marquina G et al., Cancer Res 56, pp. 5165-5171, (1996)). These research results suggest that lectins specifically recognizing carbohydrates can be adapted as an important subject in the understanding of the studies on the intercellular communications by molecular recognition, and may also be an important material in the development of diagnosing agents for a specific cancer or a therapeutic by the missile therapy in conjugation with drugs such as anti-cancer agent.

[0020] Most of the known lectins are reported to specifically recognize D-mannose and D-galactose, and those which can specifically recognize sialic acids that play important structural and functional roles at the non-reduced terminal of oligosaccharide are few. Moreover, lectins available in large amounts are extremely limited. Sialic acid-binding lectins are mainly found in invertebrate animals, and the isolated lectins are known to specifically recognize a part or entire portion of oligosaccharide similar to the lectins isolated from other origins such as plants. It was reported that mollusks and arthropods produce lectins specific to sialic acids, and that crustaceans cannot synthesize sialic acids but produce sialic acid-binding lectins as the protecting means against bacteria which express various sialoglycoconjugates.

[0021] The present invention has been accomplished by conducting various experiments with Korean marine crab Philyra pisum in order to find out a useful material from the living things in natural.

[0022] Therefore, the present invention in one aspect provides a lectin PPA which is a kind of proteins specifically recognizing N-glycolylneuraminic acid, the PPA being isolated from the hemolymph of Korean marine crab Philyra pisum.

[0023] The above lectin component is a single subunit having a molecular weight of 28.9 kDa and its N-terminal amino acid sequence is represented in sequence no. 1 of the sequence listing. This lectin component was proven to bind N-glycolylneuraminic acid or a glycoprotein containing N-glycolylneuraminic acid by hemagglutination reaction, hemagglutination-inhibition reaction or enzyme-linked immunosorbent assay (ELISA).

[0024] The present invention in another aspect provides a process for preparing the lectin PPA from Korean marine crab Philyra pisum.

[0025] Specifically, the lectin PPA can be prepared by adding an aqueous 0.15M NaCl solution to the hemolymph of Korean marine crab Philyra pisum under stirring, filtering the precipitation off, isolating a supernatant by centrifugation for 5 hours at 4° C. with 100,000 g and subjecting the supernatant to Sephadex G-25 column chromatography to isolate the protein component.

[0026] In addition to the above method, the lectin PPA can be isolated by an affinity column in which an hemagglutination-inhibition substance such as bovine submaxillary mucin and tyroglobulin, etc. is bound to an affinity column manufacturing material such as CNBr-activated Sepharose 4B as will be described in detail in Example 5.

[0027] The present invention in further aspect provides the use of the lectin PPA as diagnostics for a disease in which the structure of carbohydrates within the cells is modified to N-glycolylneuraminic acid that does not exist in normal body, which comprises the lectin PPA. The examples of the disease may include, but not limited thereto, breast cancer, melanoma or colon cancer.

[0028] As result of testing biological activity of the PPA, the lectin PPA was shown to specifically binds to N-glycolylneuraminic acid as a monosaccharide and to bovine submaxillary mucin or tyroglobulin containing N-glycolylneuraminic acid as a glycoprotein. Therefore, the lectin PPA can be used as diagnostics based on the principle that it specifically recognizes N-glycolylneuraminic acid which does not present in normal cells but specifically expressed in the cell of breast cancer, melanoma or colon cancer.

[0029] The present invention in still further aspect provides an anti-proliferation agent which comprises the lectin PPA as an active component.

[0030] The lectin PPA according to the present invention can be used as diagnostics or a carrier protein since it selectively recognizes and binds to N-glycolylneuraminic acid or a glycoprotein containing N-glycolylneuraminic acid as demonstrated by the hemagglutination reaction, hemagglutination-inhibition reaction or ELISA. In addition, the lectin PPA itself has an anti-cancer effect as shown in the test examples which will be described in detail. Therefore, the lectin PPA of the invention can also be used as an active component of an anti-proliferation agent against cancer cells (or an anti-cancer agent) in diseases in which N-glucolylneuraminic acid exists. Examples of the diseases may include, but not limited thereto, hepatoma, bladder cancer, lung cancer, stomach cancer and colon cancer.

[0031] The pharmaceutical composition of the anti-proliferation agent against cancer cells according to the present invention can be prepared in combination with the conventional pharmaceutically acceptable carrier. Generally, the active component is mixed with a pharmaceutically acceptable liquid or solid carrier. If necessary, additives such as solvent, dispersant, emulsifier, buffer, stabilizer, diluent, binder, disintegrant, lubricant, etc. can be used. The composition may be in the form of solid formulations such as tablet, granule, powder or capsule, or liquid formulations such as normal liquid, suspension or oil. These formulations may also be made as dry preparations which can be used in the liquid form by addition of a proper carrier before use.

[0032] The pharmaceutical composition of the present invention can be administered orally or parenterally, i.e., by way of injection or drop means.

[0033] The pharmaceutically acceptable carriers may be selected according to the mode of administration and formulation. In case of oral formulations, for example, the carriers include starch, lactose, refined sugar, mannite, carboxymethylcellulose, corn starch, or inorganic salts. In the preparation of oral formulations, binder, disintegrant, surfactant, lubricant, fluidity enhancer, sweetening agent, coloring agent or spicery can be additionally used.

[0034] The parenteral formulation is prepared by dissolving or suspending the composition containing the lectin PPA as the active component of the present invention in a diluent, such as distilled water for injection, physiological salt solution, aqueous glucose solution, vegetable oil for injection, sesame oil, peanut oil, soybean oil, corn oil, propylene glycol or polyethylene glycol and, if necessary, adding disinfectant, stabilizer, tonic agent or analgesic agent.

[0035] The pharmaceutical composition of the invention can be administered via a proper route depending on the formulation. The administration mode includes, but not specifically limited to, internal, external or injection. For injection administration, intravenous, intrmuscular, subcutaneous or intradermal injection is possible.

[0036] The amount of the pharmaceutical composition to be administered can properly be determined according to the formulation, the administration route, the purpose of use and the patient's age, weight or symptoms. The amount of the active component in the preparation is, for example, 10 μg to 200 mg/kg (weight) a day for an adult. Of course, the dosage varies depending on the conditions and the actual dosage may be greater or less than the above range.

[0037] The present invention in still further aspect provides a drug conjugate in which the lectin PPA as a carrier protein for local transport of a drug and a selective drug for a disease as an active agent (for example, an anti-cancer drug) are bonded, wherein the active agent is used for the disease in which the structure of carbohydrates within the cell has modified to N-glycolylneuraminic acid that does not present in a normal body. Namely, the lectin PPA of the present invention can be used as a carrier protein for local transport of a drug since it can specifically recognize N-glycolylneuraminic acid. The active agent as used herein may be selectively used from the known anti-cancer agents. The examples of the cancer include, but not limited to, breast cancer, melanoma or colon cancer.

[0038] Hereinafter, the present invention will be described in detail by way of the following examples, which are not intended to limit the scope of the present invention.

EXAMPLE 1 Isolation of Lectin PPA from Korean Marine Crab Philyra pisum

[0039] Korean marine crabs Philyra pisum collected in May through June was washed with distilled water three times. The hemolymph was taken by cutting body and legs, well mixed with a 5× diluted 0.15M NaCl solution, and then filtered with a 0.2 μm syringe filter. Subsequently, the mixture was centrifuged for 5 hours at 4° C. with 100,000×g. The supernatant thus separated was applied onto Sephadex G-25 column. For the column chromatography, 3 g of the Sephadex G-75 were equilibrated by swelling into distilled water (60 ml), running through the column to fill 40 ml of the gel, and then washing with PBS three times. 1 ml of the supernatant obtained by the centrifugation of hemolymph was loaded on the column. The resulting chromatogram was made by recording absorbance at 280 nm with a UV/VIS spectrometer. The results were represented in FIG. 1. The results were irrespective of the sex of the crabs.

EXAMPLE 2 Determination of Purity and Molecular Weight of the Lectin PPA

[0040] To determine the molecular weight and the purity of the 6-th faction (this was identified as lectin PPA by the same methods as Examples 4 and 5) in the chromatogram obtained in Example 1, an electrophoresis analysis was performed on a 12% polyacrylamide gel including 0.1% SDS to compare the molecular weight with the standard substance. After the running, the protein band was stained with a coomassie blue reagent. The results are shown in FIG. 2, in which lane 1 is a molecule marker (200, 116, 97, 66, 45, 31, 22.1, 14.4, 6.5 kDa); lane 2 is a stock solution of crab Philyra pism; lane 3 is the isolated lectin PPA of crab Philyra pisum; and lane 4 is the isolated lectin PPA of crab Philyra pisum (with 2-mercaptoethanol).

[0041] As can be seen from the results of the electrophoresis in FIG. 2, one band having a molecular weight of about 28.9 kDa was detected in the non-reduced state without addition of 2-mercaptoethanol. A 28.9 kDa band was detected in the reduced state with addition of 2-mercaptoethanol. From the above results, it was confirmed that the PPA is a protein having one subunit and a molecular weight of 28.9 kDa.

EXAMPLE 3 Analysis of N-Terminal Amino Acid of the Lectin PPA

[0042] The N-terminal amino acid of the lectin PPA isolated from Korean marine crab Philyra pisum was determined with an amino acid sequencer (Model: Automatic Protein Sequencer, 476A-01-120, Manufacturer: Applied biosystems) according to the manufacturer's instructions. It was revealed that the N-terminal amino acid sequence contains Ile-Val-Gly-Gly-Thr-Glu-Ala-Thr-Pro-His (Sequence No. 1).

EXAMPLE 4 Hemagglutination Assay of the Lectin PPA

[0043] Hemagglutination assay was performed using the 6-th fraction in the chromatogram obtained in Example 1 by diluting human, dog, mouse, rat and rabbit serums with a 10 mM phosphate buffer and 0.15M NaCl (pH 7.2) to a concentration of 6.25%. The fractions revealed positive response in the assay were collected and subjected to electrophoresis as shown in FIG. 2 to detect a single band, which was designated as PPA (Philyra pisum agglutinin; this lectin component is conveniently referred to as “PPA” in the description and the claims of the present invention). Human blood group (A, B and O type), dog, mouse, rat and rabbit erythrocytes were diluted in the same manner as described above. Each 100 μl of the erythrocytes was allowed to stand at room temperature together with 100 μl of the lectin PPA to detect the hemagglutination reaction. As a result, any agglutination was not observed in the human and dog erythrocytes that include only N-acetylneuraminic acid. However, agglutination occurred in the mouse and rat erythrocytes (diluted up to 128-fold) and the rabbit erythrocyte (diluted up to 8-fold) that include N-glycolylneuraminic acid. The results are as shown in Table 1. TABLE 1 Minimal hemagglutination Erythrocyte Type of sialic acid inhibiting activity Human type A NeuAc − Human type B NeuAc − Human type O NeuAc − Dog NeuAc − Mouse NeuGc, NeuAc, 128 O-acetylsialic acid Rat NeuGc, NeuAc, 128 O-acetylsialic acid Rabbit NeuGc, NeuAc,  8 O-acetylsialic acid

[0044] The above results show that the lectin PPA selectively recognizes N-glycolylneuraminic acid only and inhibits agglutination of the lectin PPA up to 128-fold dilution in the mouse and rat erythrocytes, this indicating that the lectin PPA exists at a concentration of about 128 μg/ml since the above value is the minimum concentration for agglutination in the case where the concentration of the concentrated lectin solution is about 1 μg/ml.

EXAMPLE 5 Hemagglutination-Inhibition Assay of the Lectin PPA

[0045] In order to confirm that the lectin PPA of the present invention recognizes N-glycolylneuraminic acid, hemagglutination-inhibition reaction was performed using monosaccharide, disaccharide and glycoprotein. 50 μl of a 128-fold diluted solution of lectin PPA in 0.15 M NaCl and 50 μl of each 1 mg/ml solution of monosaccharides (e.g., β-D-glucose, D-galactose, L-fucose, D-mannose, N-acetylneuraminic acid, N-glycolylneuraminic acid, N-acetyl-D-glucosamine, N-acetyl-D-galactosamine and methyl-α-D-glucopoyranoside), disaccharide (e.g., α-lactose, β-lactose, D-lactose, β-gentiobiose, maltose, D-raffinose or D-cellobiose) and glycoprotein (e.g., bovine submaxillary mucin, thyroglobulin, fetuin and asialofetuin) in 0.15 M NaCl were added to the each well of a 96-well microplate. After the reaction for one hour or more at room temperature, 50 μl of the erythrocyte suspended in 0.15 M NaCl was added to each well and reacted for one hour at room temperature. The results are as shown in Table 2. TABLE 2 Erythrocyte agglutination Type of inhibition Division Carbohydrate sialic acid concentration Monosaccharide β-D-glucose − − D-galactose − − L-fucose − − D-mannose − − N-acetylneuraminic NeuAc − acid N-glycolylneuraminic NeuGc 0.19 mM acid N-acetyl-D- − − glucosamine N-acetyl-D- − − galactosamine Methyl-α-D- − − glucopyranoside Disaccharide α-lactose − − β-lactose − − D-lactose − − β-gentiobiose − − Maltose − − D-raffinose − − D-cellobiose − − Glycoprotein Bovine submaxillary NeuGc/  1.3 μM mucin NeuAc/O- acetylsialic acid Thyroglobulin NeuGc  0.4 μM Fetuin NeuAc − Asialofetuin − −

[0046] As can be seen from the results of Table 2, N-glycolylneuraminic acid as a monosaccharide, and bovine submaxillary mucin and thyroglobulin containing N-glycolylneuraminic acid as glycoproteins only inhibited the agglutination, while the other monosaccharides, disaccharides and glucoproteins did not inhibit agglutination.

[0047] In Table 2, the minimum hemagglutination-inhibition concentration represents the minimum concentration for the 6.25% mouse erythrocyte which revealed the minimum hemagglutination-inhibition by diluting the lectin PPA to 128-folds that showed minimum agglutination and diluting 2-folds each of 100 mM monosaccharide/disaccharide and 100 μM glycoprotein. The negative sign (−) means that there is no hemagglutination-inhibition for 100 mM monosaccharide/disaccharide and 100 μM glucoprotein. NeuGc and NeuAc represent N-glycolylneuraminic acid and N-acetylneuraminic acid, respectively.

EXAMPLE 6 Hemagglutination Inhibition Assay of the Lectin PPA by ELISA

[0048] In order to more accurately verify the hemagglutination-inhibition reaction of the lectin PPA, ELISA was conducted. Specifically, the lectin PPA bound to a horse radish peroxidase (HRP) was used in examining the reactivity and sensitivity against glucoproteins by ELISA. First, 5.03 mg of HRP were dissolved in 0.2 ml of a 1.25% glutaraldehyde (EM grade)-100 mM sodium phosphate buffer (pH 6.8) and allowed to stand for 18 hrs at room temperature. Then, 20 μl of glycerol and 20 μl of xylene cyanol were added thereto and this was used in performing gel filtration with a Sephadex G-75 column substituted with a 100 mM phosphate buffer and 0.15M NaCl (pH 7.2). After applying the glutaraldehyde-treated HRP onto the column and eluting with 0.15M NaCl, about 1 ml of the brownish fraction containing HRP solution was collected. This fraction was dialyzed with a 100 mM sodium carbonate-sodium bicarbonate buffer solution (pH 9.5) containing sucrose and followed by the same buffer without sucrose. To 300 μl of HRP thus obtained were added 150 μl of lectin PPA (concentration of about 0.4 mg/ml concentration) substituted with 0.15M NaCl. After confirming the pH value 9.0 or more, the resultant solution was incubated for 24 hours at 4° C. to prepare peroxidase-labeled lectin PPA. Meantime, Each 1 mg of fetuin, asialofetuin and bovine submaxillary mucin was dissolved in 1 ml of PBS and repeatedly diluted to 10-folds. Each 100 μl of the 10³ to 10⁸-fold diluted solutions was then coated on each well of a 96-well microplate and reacted for 1 hr at 37° C. After removing the coated solution by aspiration, each well was washed with 100 μl of PBS and 0.1% Tween 20 (PBST) three times and reacted with 100 μl of PBS containing 1% BSA as a blocking solution for 1 hr at 37° C. The reaction solution was removed by aspiration and each well was washed with 100 μl of PBST three times. To each well were added 100 μl of the peroxidase-labeled PPA and the solution was reacted for 1 hr at 37° C. After removing the coated solution by aspiration, each well was washed with 100 μl of PBST five times. Each 100 μl of the solution prepared by adding 5 μl of H₂O₂ to 5 ml of ABTS in PBS was added to each well. Then, the absorbance at 415 nm of each well was measured with a microplate reader. To eliminate the error of each well caused by the time difference while adding ABTS, a second measurement was performed after 10 minutes to determine the difference in the absorbances between the time of 10 minutes and 0 minute. The results are shown in FIG. 3. As can be seen from FIG. 3, when each 1 mg/ml of fetuin, asialofetuin and bovine submaxillary mucin solution was diluted to 10³ to 10⁸-folds, no response was occurred in the fetuin and asialofetuin samples which do not contain N-glycolylneuraminic acid. However, a response in which absorbance value is increased was observed in the 10³-fold diluted BSM solution in which N-glycolylneuraminic acid is bounded. The absorbance was decreased with the lowering of the concentration. This result supports the use of the lectin PPA of the present invention as a diagnosing agent or a carrier protein.

EXAMPLE 7 Anti-Proliferation Effect of Lectin PPA on Cancer Cell

[0049] The anti-proliferation effect of the lectin PPA on cancer cells was evaluated using MTT (3-[4,5-dimethyldiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay (See Mosmann T et al., J. Immunol. Methods 65, pp 55-63 (1983)). Each cancer cell was cultured in a 90% RPMI 1640-10% FBS (fatal bovine serum) medium. Using a hematocytometer, the number of cells was determined as about 1×10⁴ per 100 μl. Then, the sample was added to the wells of a 96-well microplate. After addition of 100 μl of 1 μM lectin PPA, the plate was allowed to stand for 72 hours in an incubator maintaining 5% CO₂. To each well were added 50 μl of the MTT reagent and allowed to stand for 4 hours at the CO₂ incubator. After discarding the supernatant and adding 150 μl of dimethyl sulfoxide, the sample solution was mixed for 10 minuutes and measured the absorbance at 540 nm with the microplate. As a control, the same experimental procedure was performed under the above conditions without adding the lectin PPA. The percentage of proliferation was designated as 100% for the control and the relatively decreased percentage of proliferation for the samples containing the lectin PPA was compared to the control. The same procedures were repeated three times to express the decreased percentage as average value±standard deviation. As can be seen from the results of Table 3, 1 μM of lectin PPA showed anti-proliferation effects of 15.9±2.9% for human hepatoma cell Hep3B, 8.8±2.2% for human bladder cancer cell T24, 32.5±2.5% for human lung cancer cell A549, 21.9±4.8% for human stomach cancer cell SNU-C1 and 18.6±1.8% for human colon cancer cell SNU-1 (all of the cell lines as used herein were purchased from the Korean Cell Line Bank (KCLB)). TABLE 3 Origin of Name of Anti- cancer cell cancer Composition of medium proliferation % Human Hep3B RPMI 1640 90%, FBS 10% 15.9 ± 2.9% hepatoma Human bladder T24 RPMI 1640 90%, FBS 10%  8.8 ± 2.2% cancer Human lung A549 RPMI 1640 90%, FBS 10% 32.5 ± 2.5% cancer Human SNU-C1 RPMI 1640 90%, FBS 10% 21.9 ± 4.8% stomach cancer Human colon SNU-1 RPMI 1640 90%, FBS 10% 18.6 ± 18% cancer

EXAMPLE 8 Pharmaceutical Preparation

[0050] Type of preparation (tablet) Active component (lectin PPA) 10 mg Lactose 80 mg Starch 17 mg Magnesium stearate  3 mg Crystalline cellulose 10 mg

[0051] The tablets were prepared by the conventional method so as to contain the above-mentioned ingredients per tablet. If necessary, the tablets may additionally include an enteric coating (e.g., hydroxypropylmethylcellulose phthalate), a sugar coating or a film (e.g., ethyl cellulose).

INDUSTRIAL APPLICABILITY

[0052] The lectin PPA prepared by the present invention which specifically recognizes N-glycolylneuraminic acid can be used as diagnostics based on the principle that it specifically recognizes N-glycolylneuraminic acid which does not present in normal cells but specifically expressed in the cell of breast cancer, melanoma or colon cancer and can also be used as a carrier protein for local transport of a selective drug, in which the side effect is minimized by conjugating lectin with anti-cancer agents for breast cancer, melanoma and colon cancer, etc. In addition, since the lectin PPA has various beneficial biochemical characteristics, it can also be used as an anti-proliferation agent for cancer cells of hepatoma, bladder cancer, lung cancer, stomach cancer and colon cancer.

1 1 1 10 PRT Philyra pisum PEPTIDE (1)..(9) N-Terminal 1 Ile Val Gly Gly Thr Glu Ala Thr Pro His 1 5 10 

What is claimed is:
 1. A lectin PPA extracted from the hemolymph of Korean marine crab Philyra pisum which is characterized in that it is a single subunit having a molecular weight of 28.9 kDa and its N-terminal amino acid sequence is represented in sequence no. 1 of the sequence listing.
 2. The PPA protein as claimed in claim 1, wherein it binds to N-glycolylneuraminic acid or a glycoprotein including N-glycolylneuraminic acid by hemagglutination reaction, hemagglutination-inhibition reaction or enzyme-linked immunosorbent assay (ELISA).
 3. A process for preparing a lectin PPA protein from the hemolymph of Korean marine crab Philyra pisum, which comprising the steps of: diluting the hemolymph of Philyra pisum with NaCl, filtering the precipitate off and centrifuging the resulting solution to isolate a supernatant; and applying the supernatnat onto a Sephadex G-25 column or onto an affinity column prepared by binding bovin submaxillary mucin or thyroglobulin and an affinity column-manufacturing material to isolate the PPA protein.
 4. A diagnosing agent for a disease in which the structure of carbohydrates within the cells is modified to N-glycolylneuraminic acid that does not exist in normal body, which comprises the lectin PPA.
 5. The diagnosing agent as claimed in claim 4, wherein the disease is a cancer.
 6. A drug conjugate in which the lectin PPA protein according to claim 1 as a carrier protein for local transport of a drug and a selective drug as an active agent are bonded,
 7. The drug conjugate as claimed in claim 6, wherein the active agent is a drug for treatment of a disease in which the structure of carbohydrates within the cell is modified to N-glycolylneuraminic acid that does not exist in a normal body.
 8. The drug conjugate as claimed in claim 6, wherein the disease is a cancer.
 9. The drug conjugate as claimed in claim 8, wherein the disease includes breast cancer, melanoma and colon and rectal cancer.
 10. An anti-proliferation agent for cancer cells comprising the lectin PPA protein according to claim 1 as an active agent.
 11. The anti-proliferation agent for cancer cells as claimed in claim 10, wherein the cancer includes hepatoma, bladder cancer, stomach cancer and colon and rectal cancer. 